Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC‑MS/MS combined with iTRAQ technology

  • Authors:
    • Peng-Fei Zhang
    • Gu-Qing Zeng
    • Lun-Zhao Yi
    • Jian-Ping Liu
    • Xun‑Xun Wan
    • Jia-Quan Qu
    • Jian-Huang Li
    • Cui Li
    • Can-E Tang
    • Rong Hu
    • Xu Ye
    • Yu Chen
    • Zhu-Chu Chen
    • Zhi-Qiang Xiao
  • View Affiliations

  • Published online on: May 15, 2013     https://doi.org/10.3892/or.2013.2477
  • Pages: 341-349
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To discover novel lung adenocarcinoma (AdC) biomarkers, isobaric tags for relative and absolute quantitation (iTRAQ)-tagging combined with 2D-LC-MS/MS analysis was used to identify differentially expressed plasma membrane proteins in lung AdC and paired paraneoplastic normal lung tissues (PNLTs) adjacent to tumors. In this study, significant caveolin-1 downregulation and integrin β1 upregulation was observed in primary lung AdC vs. PNLT. As there has been no report on the association of integrin β1 with lung AdC, immunohistochemical staining was performed to detect the expression of integrin β1 in an independent set of archival tissue specimens including 42 cases of PLNT, 46 cases of without lymph node metastasis primary AdC (non-LNM AdC) and 62 cases of LNM AdC; the correlation of their expression levels with clinicopathological characteristics and clinical outcomes were evaluated. Based on the data, upregulation of integrin β1 was significantly correlated with advanced clinical stage and lymph node metastasis. Integrin β1 overexpression was significantly associated with advanced clinical stage (P<0.05), lymph node metastasis (P<0.05), increased relapse rate (P<0.05) and decreased overall survival (P<0.05) in AdCs. Cox regression analysis indicated that integrin β1 overexpression is an independent prognostic factor. The data suggest that integrin β1 is a potential biomarker for LNM and prognosis of AdC and integrin β1 upregulation may play an important role in the pathogenesis of AdC.
View Figures
View References

Related Articles

Journal Cover

July 2013
Volume 30 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang P, Zeng G, Yi L, Liu J, Wan XX, Qu J, Li J, Li C, Tang C, Hu R, Hu R, et al: Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC‑MS/MS combined with iTRAQ technology. Oncol Rep 30: 341-349, 2013
APA
Zhang, P., Zeng, G., Yi, L., Liu, J., Wan, X., Qu, J. ... Xiao, Z. (2013). Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC‑MS/MS combined with iTRAQ technology. Oncology Reports, 30, 341-349. https://doi.org/10.3892/or.2013.2477
MLA
Zhang, P., Zeng, G., Yi, L., Liu, J., Wan, X., Qu, J., Li, J., Li, C., Tang, C., Hu, R., Ye, X., Chen, Y., Chen, Z., Xiao, Z."Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC‑MS/MS combined with iTRAQ technology". Oncology Reports 30.1 (2013): 341-349.
Chicago
Zhang, P., Zeng, G., Yi, L., Liu, J., Wan, X., Qu, J., Li, J., Li, C., Tang, C., Hu, R., Ye, X., Chen, Y., Chen, Z., Xiao, Z."Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC‑MS/MS combined with iTRAQ technology". Oncology Reports 30, no. 1 (2013): 341-349. https://doi.org/10.3892/or.2013.2477